Stay updated with breaking news from Macula Associates. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The molecule is being evaluated in 2 phase 3 clinical trials for wet AMD and is administered via intravitreal injection in combination with standard-of-care anti–VEGF-A therapy.
A headline year for retina disease drug development concurrently brought about research and discussion into the safety outcomes of these new agents.
From a novel acne cream to a breakthrough depression drug, a half-dozen agent decisions are coming through in the coming 6 months.
/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a virtual investor day on July 11, 2023. During the event, members of...
Also from ASRS: gene therapy for retinitis pigmentosa, anti-VEGF implant matches injection